Drugs and Cardiotoxicity in HIV and AIDS
- 1 November 2001
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 946 (1) , 179-199
- https://doi.org/10.1111/j.1749-6632.2001.tb03912.x
Abstract
Abstract:The advent of potent antiretroviral drugs in recent years has had an impressive impact on mortality and disease progression in HIV‐infected patients, so that issues related to long‐term effects of drugs are of growing importance. Hyperlipidemia, hyperglycemia, and lipodystrophy are increasingly described adverse effects of highly active antiretroviral therapy (HAART), in particular when protease inhibitors are used. Hyperlipidemia is strikingly associated with the use of most available protease inhibitors, with an estimated prevalence of up to 50%. Because of the short observation period and the small number of cardiovascular events, epidemiological evidence for an increased risk of coronary heart disease in HIV‐infected patients treated with HAART is not adequate at present; however, it is likely that shortly more data will accumulate to quantify this risk. Before starting HAART and during treatment it is reasonable to evaluate all patients for traditional coronary risk factors, including lipid profile. Among the drugs that are currently used in HIV+patients, antibacterials, antifungals, psychotropic drugs and anti‐histamines have been associated with QT prolongation or torsade de pointe, a life‐threatening ventricular arrhythmia. Among the risk factors that may precipitate an asymptomatic electrocardiographic abnormality into a dangerous arrhythmia is the concomitant use of drugs that share the CYP3A metabolic pathway. Since most protease inhibitors are potent inhibitors of CYP3A, clinicians should be aware of this potentially dangerous effect of HAART. Anthracyclines are potent cytotoxic antibiotics that have been widely used for the treatment of HIV‐related neoplasms. Their cardiotoxicity is well known, ranging from benign and reversible arrhythmias to progressive severe cardiomyopathy. The increased survival and quality of life of HIV+patients emphasize the importance of a high awareness of adverse drug‐related cardiac effects.Keywords
This publication has 105 references indexed in Scilit:
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Comparative Tolerability of the Newer Fluoroquinolone AntibacterialsDrug Safety, 1999
- Unbedenklichkeitsaspekte bei der Anwendung von pegyliertem liposomalem Doxorubicin bei KrebspatientenDrugs, 1997
- Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: Evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patientsCancer, 1996
- Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virusThe Journal of Pediatrics, 1995
- The mortality of rheumatoid arthritisArthritis & Rheumatism, 1994
- Clinical Toxicity of the InterferonsDrug Safety, 1994
- Reversible Cardiac Dysfunction Associated with Interferon Alfa Therapy in AIDS Patients with Kaposi's SarcomaNew England Journal of Medicine, 1989
- Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast CancerNew England Journal of Medicine, 1988